他汀联合依折麦布与双倍剂量他汀对冠心病患者MACE影响的Meta分析
DOI:
作者:
作者单位:

(1.航天中心医院药剂科,北京市 100049;2.北京医院药学部 国家老年医学中心,北京市 100730)

作者简介:

李春杏,硕士,药师,研究方向为临床药学, E-mail为2008yuejuan@163.com。 通信作者纪立伟,硕士,主任药师,研究方向为临床药学与药物警戒,E-mail为jlw1228@sina.com。

通讯作者:

基金项目:

北京市科技计划课题(D181100000218003)


Comparison of the effects of ezetimibe co-administered with statins versus statins dose-doubling on major adverse cardiovascular events in patients with coronary heart disease:a Meta-analysis
Author:
Affiliation:

1. Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, China;2. Department of Pharmacy, Beijing Hospital, Beijing 100730, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 系统评价他汀联合依折麦布与双倍剂量他汀对冠心病患者主要不良心血管事件(MACE)的影响,为临床治疗提供参考。方法 计算机检索The Cochrane Library、PubMed、Embase、CNKI、CSTJ、CBMdisc以及万方医学网,收集他汀联合依折麦布(联合组)对比双倍剂量他汀(他汀组)治疗冠心病患者的随机对照研究,提取相关资料并按照修改后的Jadad 评分量表评价纳入研究质量,采用RevMan 5.3软件进行Meta分析。结果 共纳入29篇30项随机对照研究,合计4 757例患者。Meta分析结果显示,与他汀组比较,联合组MACE(P=0.03)、再发心绞痛(P<0.001)和再发心肌梗死(P<0.001)明显降低;而两组心源性死亡、血运重建、心力衰竭及卒中发生率差异无显著性。与他汀组比较,联合组转氨酶升高(P<0.001)、肌酸激酶升高(P=0.02)和肌损伤发生率(P<0.001)等显著降低。根据他汀种类和剂量进行亚组分析,结果显示,10 mg依折麦布+20 mg阿托伐他汀组降低MACE(P=0.02)、心肌梗死发生率(P=0.003)较阿托伐他汀40 mg组更具优势。随访时间长短对研究结果未见影响。结论 对于冠心病患者,联合组治疗较他汀组在心绞痛、心肌梗死方面获益明显,心源性死亡和卒中方面差异无显著性,且不良反应发生率显著减少。

    Abstract:

    Aim To evaluate the effects of ezetimibe co-administered with statins vs statins dose-doubling on major adverse cardiovascular events in patients with coronary heart disease systematically, in order to provide evidence-based reference for clinical use. Methods The pertinent randomized controlled trials (RCTs) about ezetimibe co-administered with statins trail group and statins dose-doubling control group in the treatment of coronary heart disease were retrieved from The Cochrane Library, PubMed, Embase, CNKI, CSTJ, CBMdisc and Wan fang Database. The quality of included studies were evaluated according to modified Jadad quality scale after extracting data. Meta-analysis was performed by using RevMan 5.3 statistical software. Results A total of 30 RCTs were included,involving 4 757 patients. The results of Meta-analysis showed that compared with double-dose statins, ezetimibe-plus-statins markedly decrease major adverse cardiovascular events(P=0.03), angina(P<0.001) and myocardial infarction(P<0.001); the incidence of cardiac death, revascularization, heart failure and stroke had no significant difference in two groups; ezetimibe-plus-statins significantly decrease adverse reactions, such as transaminase elevation(P<0.001), creatine kinase elevation(P=0.02), and muscle pain, muscle weakness and other muscle injuries(P<0.001). Meta-analysis in subgroup was studied according to the kinds and dosage of statins and follow-up time, compared with atorvastatin 40 mg, ezetimibe 10 mg plus atorvastatin 20 mg showed more advantages in reducing the incidence of major adverse cardiovascular events and myocardial infarction than other subgroups. However, no effect was found on the results between a long follow-up time (≥6 months) with a short follow-up time (≤3 months). Conclusions For patients with coronary heart disease, statins combined with ezetimibe has a significant benefit in myocardial infarction and angina compared with double dose statins, but the benefit of cardiac death and stroke were not found. The incidence of adverse reactions is significantly reduced.

    参考文献
    相似文献
    引证文献
引用本文

李春杏,刘桦,纪立伟.他汀联合依折麦布与双倍剂量他汀对冠心病患者MACE影响的Meta分析[J].中国动脉硬化杂志,2019,27(3):227~235.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2018-08-31
  • 最后修改日期:2018-12-18
  • 录用日期:
  • 在线发布日期: 2019-01-28